Sino Biopharm’s Bispecific Antibody M701 Shows Promise in Malignant Effusion Trials

Sino Biopharmaceutical ( (HK:1177) ) has provided an announcement.

Sino Biopharmaceutical said subsidiary Chia Tai Tianqing will present data at the 2026 ASCO meeting from two clinical studies of M701, a CD3/EpCAM bispecific antibody targeting malignant effusions caused by advanced epithelial tumors and non-small cell lung cancer. The company positions M701 as a national Category 1 innovative drug that could address significant unmet need in malignant ascites and pleural effusion management.

In a Phase III trial in malignant ascites from gastric, colorectal and ovarian cancers, intraperitoneal M701 plus systemic therapy significantly prolonged puncture-free survival versus paracentesis, improved patient-reported quality of life, and showed a favorable safety profile with no detriment to overall survival. A Phase II study in malignant pleural effusion due to NSCLC showed M701 markedly extended puncture-free survival and achieved higher pleural effusion response rates versus standard drainage with or without cisplatin, supporting its potential to become a new standard of care in these hard-to-treat complications.

The most recent analyst rating on (HK:1177) stock is a Buy with a HK$6.50 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.

More about Sino Biopharmaceutical

Sino Biopharmaceutical is a Hong Kong-listed pharmaceutical group focused on developing and commercializing innovative drugs, particularly in oncology and other therapeutic areas. Through subsidiaries such as Chia Tai Tianqing Pharmaceutical Group, it advances national Category 1 innovative biologics aimed at improving treatment outcomes for patients with advanced solid tumors in China and global markets.

Average Trading Volume: 75,123,192

Technical Sentiment Signal: Hold

Current Market Cap: HK$92.38B

See more data about 1177 stock on TipRanks’ Stock Analysis page.